AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
2 articles.
Bangladesh All Bangladesh research →
Company · DSE:TECHNODRUG · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Techno Drugs: FY2026 EPS of BDT 1.51 against 1.76, and BDT 129.8m of overdue loan interest disclosed in October 2026
The contraceptive supplier to the government reported FY2026 EPS of BDT 1.51 against 1.76, finance expenses at 11.2% of nine-month revenue, and told DSE in October 2026 that BDT 12.98 crore of loan interest was overdue; the board kept a 10% cash dividend for non-sponsor holders.
Company · DSE:BBSCABLES · Electrical, cables & consumer durables · Analysis · 29 Oct 2026
BBS Cables: revenue fell 75% in six years as government cable tenders were cancelled; losses have reached BDT 1.1bn a year
Revenue dropped from BDT 8.5bn (FY2019) to BDT 2.1bn (FY2025); FY2025 carried BDT 426m of tender penalties and bad debts, FY2026 EPS was BDT (5.08) as announced to DSE, and NAV per share fell to BDT 22.93.